Immune Design Corp. is a clinical-stage immunotherapy company focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. It develops multiple product candidates from its discovery platforms, ZVex and GLAAS. The company was founded by Steven G. Reed and David Baltimore on February 20, 2008 and is headquartered in Seattle, WA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
50
Frequently Asked Questions
What is Market Cap of Immune Design Corp.?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Immune Design Corp. market cap is N/A.
What is the 52-week high for Immune Design Corp.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Immune Design Corp. 52 week high is N/A as of September 16, 2025.
What is the 52-week low for Immune Design Corp.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Immune Design Corp. 52 week low is N/A as of September 16, 2025.
What is Immune Design Corp. stock price today?
Immune Design Corp. stock price today is $5.85.
What was Immune Design Corp. stock price yesterday?
Immune Design Corp. stock price yesterday was $5.85.
What is the PE ratio of Immune Design Corp.?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Immune Design Corp.’s P/E ratio is None.
What is the Price-to-Book ratio of Immune Design Corp.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Immune Design Corp. P/B ratio is None.
What is Immune Design Corp.'s EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Immune Design Corp.'s EBITDA is 0.59.
What is the 50-day moving average of Immune Design Corp.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Immune Design Corp. 50-day moving average is N/A.
